Nureca Ltd
₹ 239
0.27%
17 Jun
- close price
About
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
Key Points
- Market Cap ₹ 228 Cr.
- Current Price ₹ 239
- High / Low ₹ 344 / 200
- Stock P/E 110
- Book Value ₹ 189
- Dividend Yield 0.00 %
- ROCE 3.28 %
- ROE 1.11 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Promoter holding has increased by 3.12% over last quarter.
- Company's working capital requirements have reduced from 253 days to 148 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -7.19% over past five years.
- Company has a low return on equity of -1.07% over last 3 years.
- Earnings include an other income of Rs.8.10 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 62 | 99 | 213 | 256 | 111 | 92 | 110 | 147 | |
| 53 | 90 | 152 | 200 | 126 | 102 | 117 | 147 | |
| Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | 0 |
| OPM % | 15% | 10% | 29% | 22% | -13% | -11% | -7% | 0% |
| 0 | 0 | 3 | 8 | 7 | 11 | 12 | 8 | |
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 5 |
| Tax % | 30% | 26% | 26% | 26% | -23% | -30% | 37% | 58% |
| 6 | 6 | 46 | 45 | -8 | -2 | 1 | 2 | |
| EPS in Rs | 6,230.00 | 6,400.00 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 2.18 |
| Dividend Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | 10% |
| TTM: | 34% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -46% |
| 3 Years: | 30% |
| TTM: | 196% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -31% |
| 3 Years: | -15% |
| 1 Year: | -14% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -1% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 171 |
| 0 | 10 | 4 | 4 | 3 | 3 | 5 | 2 | |
| 15 | 9 | 19 | 12 | 8 | 10 | 11 | 13 | |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
| 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 1 |
| 23 | 33 | 182 | 175 | 139 | 104 | 200 | 182 | |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| 0 | -8 | 35 | 1 | 10 | -3 | -19 | 3 | |
| -0 | -0 | -110 | -3 | -16 | 18 | 8 | 14 | |
| -0 | 8 | 92 | -7 | -2 | -1 | -0 | -20 | |
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 | -2 |
| Free Cash Flow | 0 | -8 | 34 | -5 | 10 | -4 | -21 | -3 |
| CFO/OP | 4% | -82% | 81% | 35% | -96% | 39% | 234% | 1,789% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 6 | 4 | 14 | 6 | 11 | 19 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 | 187 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 | 20 |
| Cash Conversion Cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 | 186 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 434 | 148 |
| ROCE % | 57% | 67% | 33% | -6% | -4% | -1% | 3% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Customer Base (Cumulative Users) in Thousands |
|
||||
| Debtor Turnover Ratio Days |
|||||
| Dr Trust 360 App Users Millions |
|||||
| In-house Manufacturing Share of Unit Volumes % |
|||||
| Live Distributors (Offline) Number |
|||||
| Online Revenue Contribution % |
|||||
| Retail Counters Reach Number |
|||||
| Active SKUs Number |
|||||
| Design Patents / Registrations Number |
|||||
| In-house Manufacturing Installed Capacity Units Per Annum |
|||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Nureca Limited Has informed Regarding No Change In The Aggregate Shareholding Of The Promoter And Promoter Group Of The Company Pursuant To Inter Se Transfer Of Shares.
10 Jun - 60,842 shares transferred within promoter group; total promoter holding unchanged at 68.09%.
-
Nureca Limited Has informed Regarding Disclosure Under Regulation 7(2) Of SEBI (PIT) Regulations ,2015
10 Jun - Nectar Biopharma sold 60,842 Nureca shares off-market on 09.06.2026 for ₹1.43 crore.
-
Nureca Limited Has informed Regarding Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 ('PIT Regulations')
9 Jun - Promoter Saurabh Goyal acquired 60,842 shares off-market on June 9, 2026; holding rose to 34.35%.
-
Nureca Limited Has informed Regarding Corrigendum Pursuant To The Outcome Of The Board Meeting Submitted On 29Th May,2026.
1 Jun - Corrigendum raises approved capex from ₹100 crore to ₹128 crore for Dera Bassi plant expansion.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Board approved FY26 audited results, Rs100 crore capex, CFO resignation/appointment, and AGM on 28 July 2026.
Annual reports
Concalls
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26